New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
06:55 EDTTPI, TPI, TPI, ANX, ANX, ANX, AGEN, AGEN, AGEN, CTSO, CTSO, CTSO, ATOS, ATOS, ATOS, SYN, SYN, SYN, OXBT, OXBT, OXBT, CLRX, CLRX, CLRX, BONE, BONE, BONEOneMedPlace to host a forum
6th Annual OneMedForum 2013 is being held in San Francisco on January 7-9.
News For TPI;ANX;AGEN;CTSO;ATOS;SYN;OXBT;CLRX;BONE From The Last 14 Days
Check below for free stories on TPI;ANX;AGEN;CTSO;ATOS;SYN;OXBT;CLRX;BONE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
07:39 EDTBONEBacterin announces publication of OsteoSelect DBM Putty preclinical results
Subscribe for More Information
07:30 EDTSYNSynthetic reports preclinical data to support clinical development of mAb
Synthetic Biologics announced positive preclinical research findings for SYN-005, the company's proprietary monoclonal antibody, or mAb, combination therapy for treating Pertussis. In the second pertussis study in particular, SYN-005 was associated with favorable decreases in white blood cell counts within two days and the achievement of nearly normal levels within one week. Based on positive non-human primate and murine model findings, Synthetic Biologics has filed an additional patent application around pertussis antibodies, intends to move into cGMP manufacturing of SYN-005, and intends to file an Investigational New Drug application to support a Phase I clinical trial expected to initiate during the first half of 2015. The Company also intends to request an Orphan Drug designation for SYN-005 for the treatment of Pertussis.
April 21, 2014
18:12 EDTBONEBacterin reports preliminary Q1 revenue $8.7M-$8.9M, consensus $8.5M
Subscribe for More Information
April 17, 2014
05:03 EDTTPITianyin Pharmaceutical updates on Azithromycin API export
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use